Cyclopamine

For research use only. Not for use in humans.

Catalog No.S1146 Synonyms: 11-deoxojervine

32 publications

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Cyclopamine has been cited by 32 publications

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 NWnzfY9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjWeoFKSzVyPUWuPFY3PiEQvF2= MX7TRW5ITVJ?
DOHH-2 M1LQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonaTWM2OD17LkO1Olg6KM7:TR?= Mo\ZV2FPT0WU
no-10 MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LmfmlEPTB;OT65NFM6KM7:TR?= NY\xTnpOW0GQR1XS
LS-513 NUfke206T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELTTXpKSzVyPUGxMlM2PDdizszN MXfTRW5ITVJ?
ALL-PO NUPRbmtIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrqS2FmUUN3ME2xNU44PzN2IN88US=> NF;1bWtUSU6JRWK=
8-MG-BA NYe4TFFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L2eGlEPTB;MUOuNVEzOyEQvF2= NWLlcY9WW0GQR1XS
RPMI-8402 Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonOTWM2OD1zNT64OVM4KM7:TR?= NV24bXU5W0GQR1XS
EoL-1-cell NUfPUoxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LKT2lEPTB;MUiuOVk1QCEQvF2= NHH6W4pUSU6JRWK=
NALM-6 M1v4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPrTWM2OD1zOT6wNVY4KM7:TR?= MX;TRW5ITVJ?
DEL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XZN2lEPTB;MkCuNVQ4OSEQvF2= NGTqTYdUSU6JRWK=
SR NHPOc|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzoTWM2OD1{Mz62O|E2KM7:TR?= MWHTRW5ITVJ?
697 Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1viOWlEPTB;Mk[uOlE2PSEQvF2= NXP0SoxzW0GQR1XS
COLO-829 M2L6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDTUINmUUN3ME2yOk45PDh|IN88US=> NVjGRYNpW0GQR1XS
EVSA-T Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PROWlEPTB;MkeuOVU3OSEQvF2= MYHTRW5ITVJ?
ATN-1 Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HmfWlEPTB;M{GuNlMzQSEQvF2= NGfIXFVUSU6JRWK=
L-363 M3raWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TOR2lEPTB;M{GuO|Q3OSEQvF2= NELP[2JUSU6JRWK=
LAMA-84 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTN{LkWyNVEh|ryP NXm3VnI3W0GQR1XS
NOS-1 M2r6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTN2LkK5OVYh|ryP Mmr4V2FPT0WU
BB30-HNC M2rjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\sOGlEPTB;M{SuN|MxPiEQvF2= NYr2VnhkW0GQR1XS
BC-1 NYKxfWplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPx[Yc3UUN3ME2zO{46PzR4IN88US=> MkXyV2FPT0WU
IST-SL2 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTN6LkKyOEDPxE1? NH;jSZNUSU6JRWK=
D-392MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn1cIVRUUN3ME20NE4zOjF3IN88US=> MUfTRW5ITVJ?
no-11 MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP2PZp1UUN3ME20NE42PTJzIN88US=> NF\Ve4lUSU6JRWK=
LC4-1 M{fVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvmUXFKSzVyPUSwMlg4OTZizszN MVnTRW5ITVJ?
A388 NGfLNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF71V4lKSzVyPUSyMlU5PDhizszN NUj0NVVoW0GQR1XS
NTERA-S-cl-D1 NXywdnRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LPN2lEPTB;NEKuO|A4PCEQvF2= NF61bW5USU6JRWK=
CESS Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDZTWM2OD12ND6yNlMzKM7:TR?= NVPq[4RyW0GQR1XS
RS4-11 M{\NZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLiOZNVUUN3ME20PU4xQTN6IN88US=> NVrK[lZ2W0GQR1XS
MS-1 NXHOZ4pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\xPW5YUUN3ME21NE46OzVzIN88US=> NFrOVYZUSU6JRWK=
CTV-1 Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHKTWM2OD13MT6wO|Qh|ryP M{PhdnNCVkeHUh?=
D-502MG NEXlXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfsUoZXUUN3ME21NU43OjdzIN88US=> NF3sNVRUSU6JRWK=
ML-2 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXUc|FKSzVyPUWyMlkyQTVizszN MoDBV2FPT0WU
SK-NEP-1 NWLNcIoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7NTWM2OD13Mz6zPVI{KM7:TR?= MlXJV2FPT0WU
LOXIMVI MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vmUWlEPTB;NUOuOVg5PCEQvF2= NXLtU3NzW0GQR1XS
DJM-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jxdGlEPTB;NU[uN|M6OSEQvF2= Mm\qV2FPT0WU
GI-1 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrHTWM2OD13Nj62NVQ6KM7:TR?= NE\KO5NUSU6JRWK=
IST-MES1 NG[3b5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfYPG1KSzVyPU[wMlU1QTNizszN MkLzV2FPT0WU
MV-4-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnpTWM2OD14MD62OVM5KM7:TR?= M3PkXHNCVkeHUh?=
OVCAR-4 M4frNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPsWXZKSzVyPU[zMlU3PTdizszN MnHYV2FPT0WU
KE-37 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYftdHJRUUN3ME22Ok4zPjZ6IN88US=> M3jsSXNCVkeHUh?=
D-542MG NH3D[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33uV2lEPTB;NkiuOFE{PSEQvF2= NUnGdlJoW0GQR1XS
MHH-PREB-1 NFzueYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fo[WlEPTB;N{KuPFQ1OSEQvF2= MoXHV2FPT0WU
MRK-nu-1 MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL1TWM2OD15Mz60O|A2KM7:TR?= M331d3NCVkeHUh?=
D-247MG NEXpZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTd|LkW0OFIh|ryP M{TtOnNCVkeHUh?=
OCI-AML2 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:xcndVUUN3ME23Ok46OzZ7IN88US=> NEG5OHlUSU6JRWK=
LP-1 Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq4RWFzUUN3ME24Nk45PzNzIN88US=> NV:zenRiW0GQR1XS
HCC1599 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fBWmlEPTB;OESuNlg{PyEQvF2= NU\LUYNxW0GQR1XS
KARPAS-45 M163[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYGwTodHUUN3ME24OE43QTl{IN88US=> NWLCSZQ2W0GQR1XS
BE-13 NV\Cc4hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLJTWM2OD17OT6wOFc4KM7:TR?= NUjTd3BDW0GQR1XS
GCIY M2nQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni5TWM2OD17OT6wPVU1KM7:TR?= MYXTRW5ITVJ?
BV-173 M4Hyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFyMD6zNlUh|ryP M4j0cnNCVkeHUh?=
LB2518-MEL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYWwZphEUUN3ME2xNFAvPzh7IN88US=> NWPsdFZ6W0GQR1XS
KS-1 NXy1XYcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HCTmlEPTB;MUCxMlY{QSEQvF2= M2LNeXNCVkeHUh?=
MOLT-16 NX7nfmh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFyND65PFYh|ryP NHT1ZWZUSU6JRWK=
NCI-H1770 NFLNSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPMdJRKSzVyPUGwPE44QDRizszN MXjTRW5ITVJ?
NCI-H82 NUHObFFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTFzMD65O|Yh|ryP NEnyeldUSU6JRWK=
NCCIT NF3zdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PmUWlEPTB;MUGyMlUzQSEQvF2= NWjxdngyW0GQR1XS
KALS-1 NVnGSnhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LBTWlEPTB;MUG1Mlk1OSEQvF2= MVjTRW5ITVJ?
LB2241-RCC NX\VTWc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzCXHdKSzVyPUGxOk43PzlizszN Mn7ZV2FPT0WU
HH Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nDNmlEPTB;MUG3MlM6PSEQvF2= MUTTRW5ITVJ?
HD-MY-Z NH;aVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PDcWlEPTB;MUG4MlQ5QCEQvF2= NHrJcZVUSU6JRWK=
EB-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF{Mz6wPVQh|ryP MnXEV2FPT0WU
BL-70 M1LQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni2TWM2OD1zMkOuNVI4KM7:TR?= MYDTRW5ITVJ?
K-562 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDzTWM2OD1zMk[uNlQ2KM7:TR?= NEXn[GtUSU6JRWK=
HT-144 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;kd45TUUN3ME2xN|MvOTZ2IN88US=> MUjTRW5ITVJ?
PF-382 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP0NpRKSzVyPUGzOE4{PjFizszN MUfTRW5ITVJ?
RPMI-8226 Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLDbolKSzVyPUGzOU4xPDVizszN Mn\OV2FPT0WU
NCI-H1355 Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF|NT61PFch|ryP M{fZXHNCVkeHUh?=
LXF-289 NX;qTndCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLmO5l[UUN3ME2xN|kvPzhzIN88US=> NHLYOY9USU6JRWK=
NCI-H69 NFTQPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LHeGlEPTB;MUSyMlk{OiEQvF2= MlHyV2FPT0WU
SK-MEL-1 M1LUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjaTWM2OD1zNEeuNVMh|ryP Mn3nV2FPT0WU
KARPAS-299 NXrofpNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUf5S|k2UUN3ME2xOFkvOTJizszN NH3vNG9USU6JRWK=
GB-1 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr3S|NxUUN3ME2xOFkvOzJ{IN88US=> NXXlPFNTW0GQR1XS
CMK NGDmN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;hTGlEPTB;MUS5MlUyPSEQvF2= MVjTRW5ITVJ?
MPP-89 MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rKcWlEPTB;MUW2MlA{PSEQvF2= M17YU3NCVkeHUh?=
KU812 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DFPWlEPTB;MU[xMlkxOiEQvF2= M13p[HNCVkeHUh?=
REH NG[1bJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\wZ2lEPTB;MU[yMlEzPSEQvF2= NWjie|RxW0GQR1XS
NEC8 MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTyTWM2OD1zNkWuNFI3KM7:TR?= MULTRW5ITVJ?
KP-N-YS M2exfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF4OD6zPVUh|ryP M{XE[XNCVkeHUh?=
Ramos-2G6-4C10 NIK3S|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF4OT65NVUh|ryP NVfzVJNCW0GQR1XS
Becker MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\YTWM2OD1zN{SuNVgh|ryP MonOV2FPT0WU
LB647-SCLC NVfQdWF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:xTWM2OD1zN{WuPFQ2KM7:TR?= Mn7DV2FPT0WU
LU-139 NEPDXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDOWZlCUUN3ME2xO|gvODF7IN88US=> MXTTRW5ITVJ?
QIMR-WIL MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF5OT62OFYh|ryP NH;wZ25USU6JRWK=
NCI-H1395 M1\YOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF5OT65PVYh|ryP NF22eWxUSU6JRWK=
NOMO-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLlTWM2OD1zOEKuPFUh|ryP NYKwNppMW0GQR1XS
GI-ME-N NGHQd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\0WoFFUUN3ME2xPFcvQTZ7IN88US=> M4H2UXNCVkeHUh?=
KMS-12-PE NIHxS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF6OT6yO|Mh|ryP NWP5cFR2W0GQR1XS
Daudi MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr4TWM2OD1zOUGuNVI5KM7:TR?= MX7TRW5ITVJ?
LB996-RCC MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfoTWM2OD1zOUGuOlk6KM7:TR?= MorRV2FPT0WU
NCI-H2107 MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:z[3piUUN3ME2xPVMvPzN7IN88US=> M1rEVnNCVkeHUh?=
SK-PN-DW NETIVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfMUIZKSzVyPUG5OE44OTlizszN MnTHV2FPT0WU
MC-CAR NV7IZm5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULQSFJGUUN3ME2yNFIvOjV|IN88US=> M{DBcHNCVkeHUh?=
SNB75 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TiW2lEPTB;MkKxMlk1KM7:TR?= NGjDb3FUSU6JRWK=
ES4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG0cJA2UUN3ME2yNlMvPzh|IN88US=> M1Tv[nNCVkeHUh?=
KARPAS-422 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrpT5doUUN3ME2yNlgvOzV{IN88US=> MX3TRW5ITVJ?
NCI-H1648 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XtZmlEPTB;MkK5MlQ5QSEQvF2= NWDBWm5pW0GQR1XS
ES6 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILqdVVKSzVyPUKzPU41OyEQvF2= NHv5VWFUSU6JRWK=
KNS-81-FD NGfle4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTkeI1TUUN3ME2yOFEvOTl5IN88US=> MYrTRW5ITVJ?
JAR MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7MTWM2OD1{NU[uNlI2KM7:TR?= NULiXoZ2W0GQR1XS
NB1 NFPHTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ4MD61NVYh|ryP NHLxb5ZUSU6JRWK=
D-336MG NGHWTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLQbZRsUUN3ME2yOlAvPjl6IN88US=> MnXjV2FPT0WU
BC-3 M4HaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ4NT6xO|gh|ryP Mmi5V2FPT0WU
HCC2218 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJ4Nj60NVUh|ryP M3nNdXNCVkeHUh?=
TE-9 Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LFSWlEPTB;Mk[2MlYzPyEQvF2= M4rvUHNCVkeHUh?=
LB1047-RCC M{HSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv4OZRKSzVyPUK2Ok44PTNizszN MnzzV2FPT0WU
CTB-1 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO2TIpKSzVyPUK2PU46PzNizszN MYrTRW5ITVJ?
NB7 NIfT[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jJWmlEPTB;MkexJO69VQ>? MVLTRW5ITVJ?
ST486 NYjySJYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT3c4l7UUN3ME2yO|cvPDF{IN88US=> MXjTRW5ITVJ?
HCC1187 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y3SGlEPTB;MkiyMlgyOSEQvF2= NGHDenpUSU6JRWK=
NCI-SNU-16 NVvKXG1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LDTGlEPTB;Mki0MlI1QCEQvF2= MmPNV2FPT0WU
COR-L279 NULnPIpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3oS|hFUUN3ME2yPVEvPTh2IN88US=> M{XBVnNCVkeHUh?=
ES8 NE\hXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy2c3dxUUN3ME2yPVQvOTh{IN88US=> M2Pl[nNCVkeHUh?=
U-698-M NYPuVHN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfIe|d5UUN3ME2yPVgvOjR|IN88US=> M{LodnNCVkeHUh?=
HEL NV\ieXl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nVW2lEPTB;M{C5MlE1QSEQvF2= MmXDV2FPT0WU
KINGS-1 NHzvVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHSTWM2OD1|MUCuOlc1KM7:TR?= M4rQZnNCVkeHUh?=
KY821 NH;lNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f2NGlEPTB;M{O2MlU6PSEQvF2= MnnyV2FPT0WU
MZ1-PC MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHPTWM2OD1|NEWuOlE5KM7:TR?= NXjJVlJYW0GQR1XS
LS-411N MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTN3ND62OkDPxE1? NEPhbFJUSU6JRWK=
SIG-M5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rsTWlEPTB;M{W5Mlc5OiEQvF2= MWnTRW5ITVJ?
HT NGG3UY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTN4Nz63NVEh|ryP NWHoN3d1W0GQR1XS
HC-1 NWnVdJRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq3[YlnUUN3ME2zOlcvPzh5IN88US=> M3LSenNCVkeHUh?=
NCI-H1694 M3PQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[3XGlEPTB;M{eyMlk{PCEQvF2= NXPMNWRnW0GQR1XS
BB65-RCC NXzZZ|BPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq4XndyUUN3ME2zO|YvOjR3IN88US=> NHfqb4lUSU6JRWK=
HAL-01 NXz2R4ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTN5OT64N|gh|ryP Ml7oV2FPT0WU
ARH-77 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj1SYtKSzVyPUO5OE4xODhizszN MV7TRW5ITVJ?
MZ7-mel M2\PRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LPXGlEPTB;M{m3MlI{OyEQvF2= M4f5eXNCVkeHUh?=
SIMA MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTRyMz65N|Mh|ryP MV3TRW5ITVJ?
DG-75 NYK5ZXJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfkT|k4UUN3ME20NVUvPjl6IN88US=> NYW0WFRkW0GQR1XS
HUTU-80 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF2ySpdKSzVyPUSxPU4yQDVizszN MYXTRW5ITVJ?
KNS-42 M{[xSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTR{NT64NVUh|ryP Mm[4V2FPT0WU
SH-4 NX7ldVFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTR{Nz61OlUh|ryP MoX6V2FPT0WU
L-540 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTR|MT6wN|Eh|ryP NVzBeIVjW0GQR1XS
NB10 NXvnSmc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvic2lKSzVyPUS0NU4zOzRizszN MUDTRW5ITVJ?
ES1 M2Ljb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo[2TWM2OD12NUKuO|U{KM7:TR?= NX3VXJp1W0GQR1XS
KMOE-2 NHTsWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonTTWM2OD12NU[uO|EyKM7:TR?= M{fWTHNCVkeHUh?=
MC116 MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\0cHZKSzVyPUS1PE4yOTZizszN M2rzWnNCVkeHUh?=
RCC10RGB MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG1fJVKSzVyPUS2NE4xODVizszN NFzLVppUSU6JRWK=
RL95-2 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTR4MD6yN|ch|ryP M4i2W3NCVkeHUh?=
Raji MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[1dWlEPTB;NE[4MlE1OyEQvF2= M33FZnNCVkeHUh?=
CAS-1 Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTR5Mj6wO|Mh|ryP NYfGZm17W0GQR1XS
Calu-6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLsOFVsUUN3ME20O|UvOjZ3IN88US=> NFPsfoZUSU6JRWK=
KG-1 NGP4OohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTR5OD60OEDPxE1? NUL0PXRiW0GQR1XS
LB771-HNC MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\yTWM2OD12OEKuNlMzKM7:TR?= MUDTRW5ITVJ?
ACN M1P2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\NTWM2OD12OUOuOVk6KM7:TR?= NEHR[XlUSU6JRWK=
KM12 NWrhRpJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTR7Nj61PFkh|ryP MXXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
NF-κB / Cyclin D1 / MMP2 / MMP9; 

PubMed: 23599805     


Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9. 

Gli1 / TGF-β1 / CXCR4; 

PubMed: 26137001     


Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h.

Snail / E-cadherin / Slug / Vimentin ; 

PubMed: 26859575     


SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT.

23599805 26137001 26859575
Immunofluorescence
Vimentin; 

PubMed: 24553082     


Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry.

PCNA / β-catenin; 

PubMed: 28747625     


Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times.

24553082 28747625
In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
- Collapse

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
- Collapse
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID